登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由中国医学科学院血液病医院(血液学研究所)牵头,本站收录的另外 6 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 7
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
- 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心天津医科大学总医院Tianjin Medical University General Hospital天津医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05294055,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy;
入选标准第 1 条
Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy.
排除标准第 13 条
Patients who plan to receive radiation within 30 days after transplantation
排除标准第 15 条
Patients who are participating in other clinical studies or the interval of the last dose of prior study drug to the mobilization chemotherapy is less than 4 weeks (or 5 half-lives of the study drug);
排除标准第 19 条
Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
入选标准第 5 条
White blood cell count(WBC)<2.5×109/L;
排除标准第 7 条
Absolute neutrophil count(ANC)<1.5×109/L;
排除标准第 8 条
Platelets count(PLT)<80×109/L;
排除标准第 9 条
Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min
排除标准第 10 条
AST/ALT/Total bilirubin > 2.5 X ULN;
排除标准第 11 条
Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose.
入选标准第 7 条
Patients who are pregnant or breastfeeding
排除标准第 18 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05294055,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy; Patients who had achieved at least partial response (PR); Patients who were eligible for autologous peripheral blood stem cell transplantation Age≥18 and≤65 years; Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Patients who have an estimated life expectancy of more than three months Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose. Patients must be able and willing to give written informed consent prior to any study-related procedures排除标准:Exclusion Criteria:
Patients who had previously attempted hematopoietic stem cell mobilization; Patients who had undergone previous bone marrow transplantation; Lymphoma patients with bone marrow involvement or patients with MM who had >10% bone marrow involvement at screening ; Patients with angina pectoris, myocardial infarction, coronary stent implantation, uncontrolled arrhythmias (atrial tachycardia, atrial fibrillation, persistent ventricular arrhythmias, etc.), cardiac insufficiency, Q-Tc interval >500ms, left ventricular ejection fraction (EF)<60%, or other heart diseases that the investigator considers unsuitable for hematopoietic stem cell mobilization or hematopoietic stem cell transplantation; Patients with uncontrolled pulmonary infection; Patients who had any of the following laboratory indicators: White blood cell count(WBC)<2.5×109/L; Absolute neutrophil count(ANC)<1.5×109/L; Platelets count(PLT)<80×109/L; Creatinine > 2.0 X ULN of the reference range or creatinine clearance ≤60ml/min AST/ALT/Total bilirubin > 2.5 X ULN; Patients who have received any of the following treatments: Patients who had been treated with more than 4 cycles of lenalidomide or received lenalidomide within 4 weeks prior to hematopoietic stem cell mobilization chemotherapy. Patients who previously been treated with fludarabine or melphalan; Patients who plan to receive radiation within 30 days after transplantation Patients who had received radiation therapy in the pelvis Patients allergic to Mecapegfilgrastim, pegylated granulocyte stimulating factor, granulocyte stimulating factor, or other formulations expressed by E. coli. Patients who are pregnant or breastfeeding Patients who are participating in other clinical studies or the interval of the last dose of prior study drug to the mobilization chemotherapy is less than 4 weeks (or 5 half-lives of the study drug); Patients with other conditions unsuitable for this study according to the investigator's judgment.
引自 ClinicalTrials.gov, NCT05294055, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05294055,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。